ClinicalTrials.gg
CompletedNCT05508100Updated May 24, 2024

Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

A Phase 1 interventional study of IO-108 and IO-108 + pembrolizumab in Advanced Solid Tumor, sponsored by Immune-Onc Therapeutics. Completed at 14 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-24.

Sponsored by Immune-Onc Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of IO-108 monotherapy and in combination with anti-PD-1 monoclonal antibody pembrolizumab or tislelizumab in adult patients with advanced solid tumors. The study will be conducted in 3 parts, including Part A IO-108 monotherapy dose confirmation; Part B IO-108 + anti-PD-1 dose confirmation, and Part C dose expansion.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Immune-Onc Therapeutics is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18, and \< 75.
  2. Part A and Part B Cohort 1: Patients must have or cytologically confirmed advanced or solid tumor and have failed, or have been intolerant for standard systemic therapy, or for whom no treatment known to confer clinical benefit exists.

    Part B Cohort 2 and Part C: Patient with advanced or metastatic solid tumor who meet the specific criteria.

  3. Patients have at least 1 per v1.1 as assessed by local clinical site.
  4. (ECOG) performance status 0 to 1.
  5. Patients must have adequate hematologic function, hepatic function and renal function.

Exclusion criteria

Exclusion Criteria:

  1. Patients who previously received a monoclonal antibody therapy targeting LILRB2/ILT4 (including IO-108).
  2. Patients who received chemotherapy, radiotherapy, biologic therapy, targeted therapy, immunotherapy, or other anti-cancer therapy \< 4 weeks prior to their first day of study drug administration.
  3. Requires systemic at a dose of >10 mg daily of prednisone or the dose equivalent to other systemic corticosteroid, or other agents ≤ 14 days prior to the first dose.
  4. History of radiation pneumonitis, non-infectious pneumonitis or interstitial lung disease expect for radioactive pulmonary fibrosis not requiring corticosteroid treatment.
  5. Symptomatic central nervous system (CNS) . Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Part A: IO-108 monotherapy dose confirmation

    Patients with advanced or metastatic solid tumors will be enrolled and treated with IO-108, intravenously, every 21 days.

    Biological: IO-108

  • Experimental
    Part B: IO-108 + anti-PD-1 dose confirmation.

    Patients will receive IO-108 in combination with with a fixed dose of pembrolizumab, intravenously, every 21 days; Patients will receive IO-108 in combination with with a fixed dose of tislelizumab, intravenously, every 21 days.

    Biological: IO-108 + pembrolizumab · Biological: IO-108 + tislelizumab

  • Experimental
    Part C: Dose expansion

    Patients with advanced or metastatic solid tumors who meet the specific criteria will be enrolled into one of the cohorts.

    Biological: IO-108 + pembrolizumab · Biological: IO-108 + tislelizumab

Interventions

  • BiologicalIO-108

    IO-108, intravenously, on Day 1 of each 21-day cycle.

  • BiologicalIO-108 + pembrolizumab

    Drug pages: Anti-LILRB2 Monoclonal Antibody IO-108 · Pembrolizumab

    IO-108, intravenously, on Day 1 of each 21-day cycle. Pembrolizumab will be administered intravenously on Day 1 of each 21-day cycle.

    Also known as: IO-108 + Keytruda®

  • BiologicalIO-108 + tislelizumab

    Drug pages: Anti-LILRB2 Monoclonal Antibody IO-108 · Tislelizumab

    IO-108, intravenously, on Day 1 of each 21-day cycle. Tislelizumab will be administered intravenously on Day 1 of each 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) in patients treated with IO-108

    AE severity graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0

    Time frame: through study completion, an average of 2 years

  2. Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) in patients treated with IO-108 in combination with pembrolizumab or tislelizumab

    AE severity graded by NCI CTCAE, Version 5.0

    Time frame: through study completion, an average of 2 years

  3. Preliminary anti-tumor activity of IO-108 in combination with pembrolizumab or tislelizumab

    ORR is defined as the percentage of patients who have a complete response (CR) or a partial response (PR) per RECIST v1.1

    Time frame: through study completion, an average of 2 years

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of IO-108

    Characterize the Cmax of IO-108 by successive sampling of blood at pre-specified time points

    Time frame: through study completion, an average of 2 years

  2. Steady state concentration of IO-108

    Characterize steady state concentration of IO-108 by successive sampling of blood at pre-specified time points

    Time frame: through study completion, an average of 2 years

  3. Anti-drug antibodies (ADA) of IO-108

    Determine the incidence and titer of ADAs against IO-108

    Time frame: through study completion, an average of 2 years

  4. Preliminary anti-tumor activity

    Disease Control Rate, defined as the percentage of patients with CR, PR, or stable disease.

    Time frame: through study completion, an average of 2 years

  5. Preliminary anti-tumor activity

    Progression-free Survival, defined as the time interval from the first dose date to the occurrence of disease progression or death of any cause

    Time frame: through study completion, an average of 2 years

07

Study locations

14 sites
  • The First Affiliated Hospital of Fujian Medical University
    Fujian, Fuzhou, China
  • 1st affiliated Hospital of Hainan Medical University
    Haikou, Hainan, China
  • 4th Hospitla of Hebei Medical University
    Shijia Zhuang, Hebei, China
  • Harbin Cancer Hospital
    Harbin, Heilongjiang, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • Tongji Hospital
    Wuhan, Hubei, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410031, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330052, China
  • Liaoning Cancer Hospital
    Shenyang, Liaoning, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • Lin Yi Cancer Hospital
    Linyi, Shandong, China
  • Shanghai Dong Fang Hospital
    Shanghai, Shanghai 200120, China
  • 1st Affiliated Hospital of Xi'an Jiaotong University
    Xian, Shanxi, China
  • Sir RUN RUN SHAW HOSPITAL
    Hangzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Apr 2024, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2022
First posted
Aug 19, 2022
StartActual
Sep 9, 2022
Primary completionActual
Apr 30, 2024
CompletionActual
Apr 30, 2024
Last update
May 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05508100
Lead sponsor
Immune-Onc Therapeutics
Responsible party
Sponsor
First posted
Aug 19, 2022
Start date
Sep 9, 2022
Primary completion
Apr 30, 2024
Completion
Apr 30, 2024
Last update
May 24, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-LILRB2 Monoclonal Antibody IO-108 · Pembrolizumab · Tislelizumab

Start the discussion